Quick answerInvasive meningococcal infection. Actions: give prescribed IV ceftriaxone after blood cultures; notify the provider and start Droplet Precautions. Monitor: blood pressure with heart rate, and the extent of the petechial or purpuric rash.
Why this is correctEculizumab blocks terminal complement, which is the main defense against Neisseria meningitidis. The boxed warning states that infections can become life-threatening rapidly and that vaccinated clients remain at risk. This client was vaccinated only 6 days ago and missed prophylaxis. Fever, severe myalgia, tachycardia, blood pressure 34 mm Hg below baseline, and nonblanching petechiae are early meningococcemia. The platelet count and LDH are improving, which argues against an aHUS relapse as the cause of the petechiae.
Easy analogy or mental pictureEculizumab is like switching off a building's alarm system to stop a false fire alarm (aHUS): it works, but a real burglar (meningococcus) can now walk in, so any sign of an intruder means calling security at once.
Memory hookComplement off, meningococcus on: fever plus petechiae on eculizumab = cultures, ceftriaxone, call now.
NCLEX decision ruleIn a client on a drug with a boxed infection warning, treat a new fever with hemodynamic change as the boxed-warning complication until proven otherwise; do not attribute it to a benign cause first.
Why the other choices are wrongInfluenza shares fever and myalgia but not nonblanching petechiae or relative hypotension, and cough is not the parameter that tracks meningococcemia. A post-vaccination reaction appears within 1 to 2 days and shows local injection-site changes; neither is present, so acetaminophen with a recheck delays sepsis care. aHUS relapse is tempting because of petechiae, but platelets and LDH are improving, so plasma exchange and a platelet/LDH trend target the wrong problem. Holding the next eculizumab infusion is not the immediate action and interrupting therapy risks TMA relapse; that decision belongs to the prescriber after the infection is treated.
References
1DailyMed — SOLIRIS (eculizumab) prescribing informationBoxed warning: life-threatening meningococcal infection despite vaccination; immediate evaluation of early signs.